JENNIFER READ ALLEN, PA-C
Physician Assistant in Carmel, IN
License number
Indiana 9374
Category
Nursing
Type
Physician Assistant
License number
Indiana 10001398A
Category
Nursing
Type
Physician Assistant
Address
Address
2
11911 N. Meridian St SUITE 150, Carmel, IN 46032
6266 E 75Th St SUITE 500, Indianapolis, IN 46250
6266 E 75Th St SUITE 500, Indianapolis, IN 46250
Phone
(317) 621-6701
Professional information
Coordinator
Position:
Alumni Relations and Development Coordinator at Indiana University
Location:
Indianapolis, Indiana Area
Industry:
Education Management
Work:
Indiana University
- Bloomington, Indiana Area since Jul 2011
-
Alumni Relations and Development Coordinator
Marion County Prosecutor's Office
2007 - 2011
-
Litigation Paralegal
Education:
Indiana University Bloomington 2002 - 2006
Kinesiology, Sport Marketing & Management
Kinesiology, Sport Marketing & Management
Education Management Professional
Location:
Indianapolis, Indiana Area
Industry:
Education Management
Jennifer R Allen, Carmel IN
Specialties:
Internal Medicine
Address:
11911 N Meridian St STE 150, Carmel 46032
(317) 621-6701 (Phone)
(317) 621-6701 (Phone)
Languages:
English
Education:
Medical School
Indiana University / School of Medicine
Graduated: 2011
Indiana University / School of Medicine
Graduated: 2011
Jennifer Allen - Indianapolis, IN
Work:
Redbox
warehouse associate Stop One Tanning - Crawfordsville, IN
front desk clerk Oak Hill Cemetery, Oak Hill Monuments - Crawfordsville, IN
secretary Rax Restaurants - Crawfordsville, IN
dishwasher
warehouse associate Stop One Tanning - Crawfordsville, IN
front desk clerk Oak Hill Cemetery, Oak Hill Monuments - Crawfordsville, IN
secretary Rax Restaurants - Crawfordsville, IN
dishwasher
Jennifer Read Allen, Carmel IN
Specialties:
Physician Assistant
Address:
11911 N Meridian St, Carmel, IN 46032
Glycoconjugates, Glycoamino Acids, Intermediates Thereto, And Uses Thereof
US Patent:
8623378, Jan 7, 2014
Filed:
Jan 31, 2011
Appl. No.:
13/018249
Inventors:
Samuel J. Danishefsky - Englewood NJ, US
Jennifer R. Allen - Indianapolis IN, US
Philip O. Livingston - New York NY, US
Lawrence Williams - New York NY, US
Jennifer R. Allen - Indianapolis IN, US
Philip O. Livingston - New York NY, US
Lawrence Williams - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A01N 43/04, A61K 39/385, A61K 31/70, A61K 31/715
US Classification:
4241931, 4241941, 514 193, 514 23, 514 25, 514 42, 514 53, 514 54, 514 62, 530322, 5361231
Abstract:
The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.
Glycoconjugates, Glycoamino Acids, Intermediates Thereto, And Uses Thereof
US Patent:
7854934, Dec 21, 2010
Filed:
Jul 31, 2002
Appl. No.:
10/209618
Inventors:
Samuel J. Danishefsky - Englewood NJ, US
Don M. Coltart - New York NY, US
Stacy J. Keding - New York NY, US
Kaustav Biswas - Thousand Oaks CA, US
Philip O. Livingston - New York NY, US
Jennifer R. Allen - Indianapolis IN, US
Lawrence Williams - Edison NJ, US
Don M. Coltart - New York NY, US
Stacy J. Keding - New York NY, US
Kaustav Biswas - Thousand Oaks CA, US
Philip O. Livingston - New York NY, US
Jennifer R. Allen - Indianapolis IN, US
Lawrence Williams - Edison NJ, US
Assignee:
Sloan-Kettering Institute For Cancer Research - New York NY
International Classification:
A01N 43/04, A61K 39/385, A61K 31/70, A61K 31/715
US Classification:
4241931, 514 8, 514 23, 514 25, 514 42, 514 53, 514 54, 514 62, 530322, 5361231
Abstract:
The present invention provides novel glycosides and glycoconjugates, glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycopeptides as disclosed herein, either in conjugated form or unconjugated and in combination with a suitable immunogenic carrier.
Cb1 Antagonist Compounds
US Patent:
7276516, Oct 2, 2007
Filed:
Dec 13, 2004
Appl. No.:
10/596495
Inventors:
Jennifer Rebecca Allen - Indianapolis IN, US
Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
George Stuart Gregory - Fishers IN, US
Steven Andrew Hitchcock - Westlake Village CA, US
Paul J. Hoogestraat - Indianapolis IN, US
Daryl Lynn Smith - Fishers IN, US
Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
George Stuart Gregory - Fishers IN, US
Steven Andrew Hitchcock - Westlake Village CA, US
Paul J. Hoogestraat - Indianapolis IN, US
Daryl Lynn Smith - Fishers IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A01N 43/42, A01N 43/38, A61K 31/44, C07D 471/02, C07D 491/02
US Classification:
514300, 514414, 514418, 514404, 546113, 5462771, 548469, 5483611
Abstract:
Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e. g. , multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
Cb1 Modulator Compounds
US Patent:
7595339, Sep 29, 2009
Filed:
Aug 17, 2007
Appl. No.:
11/840417
Inventors:
Jennifer Rebecca Allen - Indianapolis IN, US
Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
George Stuart Gregory - Fishers IN, US
Stephen Andrew Hitchcock - Westlake Village CA, US
Paul J. Hoogestraat - Indianapolis IN, US
Daryl Lynn Smith - Fishers IN, US
Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
George Stuart Gregory - Fishers IN, US
Stephen Andrew Hitchcock - Westlake Village CA, US
Paul J. Hoogestraat - Indianapolis IN, US
Daryl Lynn Smith - Fishers IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31/40
US Classification:
514418
Abstract:
Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e. g. , multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
Muscarinic Agonists
US Patent:
7326731, Feb 5, 2008
Filed:
Sep 9, 2002
Appl. No.:
10/488519
Inventors:
Jennifer Rebecca Allen - Indianapolis IN, US
Stephen Andrew Hitchcock - Carmel IN, US
James Andrew Jamison - Indianapolis IN, US
Bin Liu - Fishers IN, US
Stephen Andrew Hitchcock - Carmel IN, US
James Andrew Jamison - Indianapolis IN, US
Bin Liu - Fishers IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31/16, C07C 233/00
US Classification:
514613, 564161
Abstract:
The present invention relates to compounds of Formula I: Formula I which are agonists of the M-1 muscarinic receptor.